Step-wise General Clinic Management of Melasma

Fig. Melasma - characteristic hyperpigmented patches on the malar/centrofacial region

Step 1 - Initial Assessment and Diagnosis

• Identify pattern: centrofacial (most common), malar, or mandibular
• Note skin phototype (Fitzpatrick I-VI) - types III-V most affected
• Wood's lamp examination: epidermal melasma shows accentuation; dermal melasma does not (though most cases are mixed)
• Document severity using the MASI (Melasma Area and Severity Index)

• Oral contraceptives (OCP) - discontinue if possible
• Hormone replacement therapy (HRT)
• Pregnancy ("mask of pregnancy" / chloasma)
• Phenytoin or finasteride therapy
• Sun exposure history

Note: Dermal melanin deposits respond poorly to topical agents - set realistic expectations with the patient.

Step 2 - Baseline Recommendations for ALL Patients

Step 3 - First-Line Active Topical Therapy

A. Triple Combination (Kligman's Formula) - Gold Standard

• Hydroquinone 4% + Tretinoin (retinoid) + mild topical corticosteroid (class 5-7, e.g., fluocinolone acetonide 0.01%)
• Applied at bedtime
• Use daily for 2-4 months, then taper to 1-2 times/week for maintenance
• Commercially available as Tri-Luma cream

• HQ: inhibits tyrosinase, blocking melanin synthesis
• Tretinoin: increases epidermal turnover, enhances HQ penetration
• Corticosteroid: reduces inflammation and irritation from the other two agents

• Perioral dermatitis and skin atrophy (steroid overuse)
• Exogenous ochronosis (HQ overuse - progressive darkening paradoxically)
• Fixed erythema, telangiectasias, acneiform eruptions, hypertrichosis

B. Hydroquinone Monotherapy (if triple combination not tolerated)

• 2% (OTC) to 4% (prescription) HQ applied once or twice daily
• Less effective than triple combination but still the monotherapy gold standard
• Tretinoin alone can reduce melasma but is less effective than HQ

C. Azelaic Acid (15-20%)

• Useful alternative, especially in pregnancy (pregnancy category B)
• Tyrosinase inhibitor; also has anti-inflammatory properties

Step 4 - Adjunctive Topical Therapies

Step 5 - Adjunctive Oral Therapy

Oral Tranexamic Acid

• 250 mg twice daily for 8-12 weeks
• Inhibits UV-induced plasminogen activation in keratinocytes, reducing melanocyte stimulation
• Screen for thromboembolism risk factors before prescribing
• Recent systematic reviews (2024) confirm efficacy; tranexamic acid (oral and microneedling delivery) shows good safety and improvement in MASI scores

Step 6 - Second-Line Therapies (Chemical Peels)

• Glycolic acid peels: Start at 30%, increase as tolerated; every 4-6 weeks
• Salicylic acid peels: 20-30%; especially useful in oily/acne-prone skin
• TCA (trichloroacetic acid) peels: use with caution in darker skin types
• Tretinoin 1% peels: option in some protocols

Step 7 - Third-Line Therapies (Procedural / Light-Based)

Step 8 - Long-Term Maintenance (Mandatory)

• Daily SPF ≥30 broad-spectrum sunscreen - lifelong
• Topical retinoid (e.g., tretinoin 0.025-0.05%) - maintain collagen turnover
• Topical alpha-hydroxy acid (glycolic acid cream)
• Other depigmenting agents as tolerated: L-ascorbic acid, azelaic acid, kojic acid, tranexamic acid 2-5%
• Triple combination (HQ + retinoid + steroid) at reduced frequency: twice weekly

Summary Algorithm

ALL patients → Sun protection + eliminate triggers
          ↓
Step 3 → Triple combination (Kligman's formula) ± azelaic acid [2-6 months]
          ↓ (inadequate response)
Step 4+5 → Add adjunctive topicals + oral tranexamic acid
          ↓ (still inadequate)
Step 6 → Chemical peels (glycolic/salicylic acid)
          ↓ (refractory cases only)
Step 7 → Fractionated laser / IPL / picosecond laser (test spot first)
          ↓
Step 8 → Lifelong maintenance (sunscreen + retinoid + depigmenting agent)

Key Clinical Pearls

1. Set realistic expectations - melasma is chronic and prone to relapse; improvement not cure is the goal
2. Darker skin types (IV-VI) are at high risk for PIH from procedures - always test spot first
3. Dermal melasma responds poorly to topical agents; procedures may be needed
4. Pregnancy: avoid HQ and retinoids; azelaic acid is safe (category B)
5. Exogenous ochronosis is a feared complication of prolonged HQ use (>2 years) - progressive paradoxical darkening; histology shows banana-shaped deposits
6. Visible light triggers melasma just as UV does - iron oxide-containing sunscreens are preferred

Recurrence of Melasma: What are the Chances?

The Bottom Line

Recurrence Rates by Treatment Type

Key Statistics

• 50-70% of patients experience recurrence after treatment is stopped (if no maintenance is continued)
• Even with strict maintenance therapy (twice-weekly triple combination), only ~53% of patients remain relapse-free at 6 months - meaning nearly half relapse despite maintenance
• Recurrence can begin as early as 1-2 weeks after stopping triple combination therapy
• After IPL, approximately 50% relapse within 3-6 months - with one meta-analysis reporting 18.6% recurrence at 12 months for combination laser therapy (better, but still significant)
• After laser treatment, a 2025 meta-analysis (PMID 41378674) confirms significant MASI score improvements but notes recurrence as a consistent finding across 16 RCTs with 471 patients

Factors That Determine Recurrence Risk

High-risk factors (increases recurrence):

1. Ongoing sun exposure - the single biggest driver; even incidental UV re-triggers melanogenesis
2. Visible light exposure - often underestimated; penetrates ordinary sunscreens
3. Continued hormonal triggers - ongoing OCP use, pregnancy, HRT
4. Darker skin phototypes (IV-VI) - higher basal melanocyte activity
5. Severe melasma at baseline - a key predictor; severe cases relapse earlier and more completely (relapse rate significantly higher than mild cases even with maintenance, per Arellano et al.)
6. Dermal melasma - dermal melanophages are not cleared by topical agents and persist; these cases relapse faster
7. Genetic predisposition - family history of melasma
8. Non-compliance with maintenance - stopping sunscreen or depigmenting agents abruptly

Protective factors (reduces recurrence risk):

• Daily broad-spectrum SPF ≥30 with iron oxide (blocks visible light too)
• Strict sun avoidance, hats, UV-protective clothing
• Maintenance retinoid + depigmenting topical
• Eliminating hormonal triggers (stopping OCP)

Why Melasma Recurs So Readily

• Wnt pathway upregulation in melasma-affected skin remains after clinical clearing, keeping melanocytes primed
• Dermal melanophages persist after topical treatment and act as a reservoir
• Reduced WIF-1 expression (Wnt antagonist) is intrinsic, not corrected by treatment
• UV/visible light re-exposure continuously re-stimulates the hyperactive melanocytes that were never truly eliminated - only suppressed
• Hormonal influences are often ongoing and unavoidable (e.g., natural estrogen cycling)

Practical Implication for Clinic

"Recurrence is the norm despite recommended measures such as strict sun protection." - Dermatology 2-Volume Set 5e

1. Counsel patients upfront - frame treatment as ongoing management, not a cure
2. Lifelong photoprotection is non-negotiable, even after clearing
3. Maintenance therapy (retinoid + depigmenting agent) reduces but does not eliminate relapse risk
4. Seasonal variation is common - melasma worsens every summer, even in treated patients
5. Avoid over-treating with procedures in dark skin types - PIH from aggressive laser/peels can be harder to treat than the original melasma

Step-wise General Clinic Management of Melasma with Acne

Understanding the Clinical Challenge

Key principle: Acne must be controlled FIRST (or simultaneously with gentle agents) before aggressively treating melasma - active acne causes PIH which worsens pigmentation.

Step 1 - Full Initial Assessment

• Acne severity: Mild / Moderate / Severe (comedonal, inflammatory, nodulocystic)
• Melasma severity: MASI score, distribution (centrofacial / malar / mandibular)
• Skin phototype (Fitzpatrick I-VI) - darker types have higher PIH risk
• Hormonal history: OCP use, menstrual irregularity, PCOS
• Current medications: anything comedogenic or photosensitising
• Wood's lamp: epidermal vs dermal vs mixed melasma

Step 2 - Universal Baseline Measures (ALL patients, Day 1)

Photoprotection - Non-negotiable

• Broad-spectrum SPF ≥30 with physical blockers (zinc oxide / titanium dioxide) - choose non-comedogenic formulations (gel-based or fluid textures, not cream-based)
• Add iron oxide component to block visible light
• Wide-brimmed hat, sun-protective clothing
• Avoid tanning beds

Skin Care Hygiene

• Gentle, non-comedogenic, non-soap cleanser (foam or gel) twice daily
• Avoid heavy, occlusive moisturizers - use lightweight, oil-free, non-comedogenic options
• No scrubbing or mechanical exfoliation over active acne
• Discontinue OCP if feasible (reduces both hormonal acne and melasma triggers)

Step 3 - First-Line Active Treatment (Weeks 1-12)

Choose agents that address BOTH conditions simultaneously - the "dual-duty" approach

3A. AZELAIC ACID - the ANCHOR agent in this combination

3B. TOPICAL RETINOID - the "two-for-one" agent

• Treats acne by normalizing follicular keratinization and reducing comedones
• Treats melasma by increasing epidermal turnover and enhancing depigmenting agent penetration
• Reduces PIH from existing acne scars
• Use adapalene gel if irritation is a concern (better tolerability than tretinoin, especially in darker skin types)
• Start low and slow (every other night for 2 weeks, then nightly) to avoid retinoid dermatitis - which itself can trigger PIH

Note: Do NOT combine tretinoin with a topical steroid as in classic Kligman's formula - the steroid component must be dropped when acne is present.

3C. BENZOYL PEROXIDE (BPO) - use cautiously, strategically

• BPO 2.5-5% wash or leave-on gel for acne
• Do NOT apply over melasma areas - can cause irritation and paradoxical PIH in darker skin types
• If using: apply only to acne-predominant areas (e.g. forehead, jawline), avoid malar/centrofacial melasma zones
• Wash-off formulations preferred over leave-on in darker skin types
• Combine with topical antibiotic (clindamycin or erythromycin) to prevent antibiotic resistance per AAD 2024 guidelines

3D. TOPICAL ANTIBIOTICS

• Clindamycin 1% gel or lotion - for inflammatory acne over non-melasma zones
• Never as monotherapy (antibiotic resistance) - always combine with BPO or retinoid
• Clindamycin has mild anti-inflammatory effect that may reduce PIH indirectly
• Apply in AM; retinoid / azelaic acid at night

Sample AM/PM Routine at Step 3

Step 4 - Add Adjunctive Depigmenting Agents (Weeks 4-12, once acne is controlled)

Step 5 - Systemic Therapy (Moderate-Severe Acne, or Inadequate Topical Response)

5A. Oral Antibiotics (for moderate-severe inflammatory acne)

• Doxycycline 100mg once or twice daily - first choice (AAD 2024 guideline)
• Limit to 3 months maximum to minimize resistance
• Always combine with topical BPO to prevent resistance
• Photosensitizing effect of doxycycline - counsel patient to be especially strict with SPF; can worsen melasma if sun protection is lax
• Avoid tetracyclines if patient is pregnant or <12 years

5B. Oral Tranexamic Acid (for melasma component)

• 250 mg twice daily for 8-12 weeks
• Screen for thromboembolism risk before prescribing
• No interaction with acne treatments
• Systematic reviews (2024, PMID 38843906) confirm efficacy for melasma

5C. Hormonal therapy (if hormonal acne + melasma in women)

• Oral contraceptives (combined): Paradox - can help hormonal acne but may worsen melasma
• Prefer spironolactone 50-100mg/day (anti-androgen) for hormonal acne in women - does not directly worsen melasma and may help by reducing inflammation and PIH
• Avoid OCP if melasma is predominant concern; use spironolactone instead

5D. Isotretinoin (severe/nodulocystic acne)

• 20-40mg/day (weight-based) for severe acne failing topical + oral antibiotics
• Excellent choice when both conditions coexist in severe acne because:
  • Clears acne completely, eliminating PIH trigger
  • Reduces sebum - prevents new melasma-triggering inflammation
  • Allows melasma treatment to work on a "clean slate"
• Counsel: isotretinoin causes photosensitivity - strict SPF is mandatory during therapy
• After isotretinoin course, melasma can be treated more aggressively
• REMS program enrollment mandatory (iPLEDGE in USA)

Step 6 - Procedures (After Active Acne is Controlled)

Step 7 - Long-Term Maintenance

• Daily non-comedogenic SPF ≥30 - lifelong
• Topical retinoid (adapalene 0.1%) - maintains both acne control and melasma prevention
• Azelaic acid twice weekly - prevents both pigment recurrence and comedone formation
• Niacinamide or vitamin C - ongoing depigmenting and anti-inflammatory maintenance
• Review and reassess every 3-6 months
• If OCP was continued for contraception, monitor melasma closely and consider switching to non-hormonal or progesterone-only options

Summary Algorithm

ASSESS: Acne severity + Melasma severity + Skin type
         ↓
STEP 2: Non-comedogenic SPF + gentle cleanser (ALL patients, Day 1)
         ↓
STEP 3: Azelaic acid 15-20% (dual-duty) + Retinoid PM + BPO (acne zones only)
         ↓ (4-6 weeks - acne inflammation controlled)
STEP 4: Add HQ 4% (no steroid) + Niacinamide + Tranexamic acid topical
         ↓ (moderate-severe acne or inadequate response)
STEP 5: Doxycycline (acne) + Oral tranexamic acid (melasma) ± Spironolactone (hormonal acne in women)
         Severe acne: consider isotretinoin - clears acne, enables aggressive melasma Rx after
         ↓ (acne cleared, only after active lesions resolved)
STEP 6: Salicylic acid peels / Microneedling + tranexamic acid
         ↓
STEP 7: Maintenance retinoid + azelaic acid + SPF (lifelong)

Key Clinical Pearls

1. Avoid topical steroids in this combination - they worsen acne, cause steroid rosacea and perioral dermatitis, and lead to more PIH
2. Azelaic acid is the cornerstone - the only single agent that treats acne, melasma, AND PIH simultaneously
3. Control acne first, then address melasma - every active acne lesion is a PIH risk that undermines melasma treatment
4. Doxycycline = photosensitiser - if prescribing for acne, redouble the emphasis on sun protection or melasma will worsen
5. Spironolactone over OCP for hormonal acne in melasma patients - avoids the hormonal melasma trigger
6. Gel/foam/fluid formulations preferred over creams - less comedogenic for acne-prone skin
7. PIH from acne is epidermal and responds well to retinoids + azelaic acid - do not rush to add HQ until acne is controlled